NCT05838664 - A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France | Biotech Hunter

Enrollment

3,691,397

Participants

Timeline

Start Date

July 7, 2023

Primary Completion Date

March 31, 2024

Study Completion Date

March 31, 2024

Conditions

Atrial Fibrillation

Interventions

DRUG

No OAC

AF Patient who were not exposed to oral anticoagulation

DRUG

VKA

AF patients who received VKA

DRUG

apixaban

AF patients who received apixaban

DRUG

rivaroxaban

AF patients who received rivaroxaban

DRUG

dabigatran

AF patients who received dabigatran

Trial Locations (1)

Pfizer Investigational Site, Paris